Enhanced Group Inc. (ENHA) · Nov 5, 2026 · Acquisition
$15M PIPE + 77% DEAG acquisition — ~11.0M shares for 77% of DEAG; $15M PIPE; up to 5.747M warrant shares
Enhanced’s acquisition gives it control of DEAG and a projected $670M 2027 revenue platform, funded by a $15M PIPE but with substantial dilution.
Enhanced is moving from an early-stage sports and telehealth company toward an acquisition-led live-entertainment platform. The DEAG transaction is the anchor for that shift: a European promoter and ticketing business with roughly 6,000 annual events, established operations and a history of more than 30 acquisitions since 2019.
This materially advances the business story, rather than merely adding another project. Enhanced will gain majority control of a much larger operating business and expects to consolidate DEAG, giving its own sports properties access to event-production, promoter, venue and ticketing infrastructure. The company’s illustrative 2027 forecast jumps to about $670 million of combined revenue and $26 million of adjusted EBITDA, versus Enhanced’s standalone projection of $66.1 million of revenue and negative $0.4 million of adjusted EBITDA. Those figures are management estimates, unaudited, partly based on DEAG public information, and prepared under IFRS rather than U.S. GAAP—so the strategic change is real, but the earnings case is not yet demonstrated.
| Figure | 2026E | 2027E |
|---|---|---|
| Enhanced revenue (Financials — Pro forma combined financials) | $32.0M | $66.1M |
| DEAG revenue (Financials — Pro forma combined financials) | $519.6M | $603.9M |
| Combined revenue (Financials — Pro forma combined financials) | $551.6M | $670.0M |
| Enhanced adjusted EBITDA (Financials — Pro forma combined financials) | $(53.0)M | $(0.4)M |
| DEAG adjusted EBITDA (Financials — Pro forma combined financials) | $13.6M | $26.5M |
| Combined adjusted EBITDA (Financials — Pro forma combined financials) | $(39.4)M | $26.1M |
| PIPE proceeds (Private Placement) | — | $15.0M |
| DEAG consideration shares (Exchange Agreements) | — | ~11.0M |
| Additional June warrant shares (Warrant Adjustment) | — | Up to 5.747M |
The financing supports the pivot, but the equity cost is substantial. The $15 million PIPE is priced at $7.11, equal to the prior closing price, so it supplies capital without a financing premium. More importantly, Enhanced plans to issue roughly 11 million shares for DEAG while also issuing 2.109 million PIPE shares; against approximately 13.7 million existing Class A shares shown in the presentation, that nearly doubles the share base before the warrant reset is considered. The June 2026 warrants also reset to $7.11 and can increase by up to 5.747 million shares. That means the transaction buys operating scale with a very large expansion in potential claims on the company.
The deal’s strongest feature is the asset being acquired, not the certainty of the forecast. Enhanced says DEAG is being acquired at about 5.3 times estimated 2027 lease-adjusted EBITDA, below the cited 14.1-times listed-peer median. But DEAG’s financials are not yet converted to U.S. GAAP, the projections were prepared by Enhanced rather than DEAG, and the transaction does not include modeled synergies. In addition, Enhanced initially controls only 77% of DEAG; any path to 100% ownership remains optional and unspecified, while debt covenants and change-of-control provisions could affect cash access and closing.
Execution and governance remain meaningful qualifications. Apeiron controls Enhanced and is also selling DEAG shares, making this a related-party transaction. The independent special committee and fairness opinion add process protection, but the transaction was approved through controlling-stockholder written consent rather than a vote of the other shareholders. Closing still depends on consent, regulatory approvals, an APLOF valuation condition and DEAG debt-related conditions. 〔0〕
Bottom line: This is a genuine rewrite of Enhanced’s operating ambition: from a small, unproven sports and health platform to a live-entertainment and ticketing consolidator with immediate scale. The development is clearly positive for the business story, but it is conditional on closing and execution, and existing holders pay for the transformation through heavy dilution and warrant overhang.
Closing after stockholder consent, Schedule 14C and regulatory approvals
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!